ESR1 and breast cancer: We observed no association using Bayesian joint models between CYP2C19 inhibiting medication use and breast cancer recurrence among the ER+/T+ patients (i.e., ≥ 50% vs. 0%, HR = 1.0, 95% CrI: 0.69, 1.40).